- Market cap then
- INR 485 Cr.
KRM Ayurveda Ltd has shifted from Ayurvedic product sales towards hospitals, clinics and related healthcare services. The note provides no share target price or recommendation; it highlights service growth while flagging working-capital demands, related-party sales and promoter litigation.
About KRM Ayurveda
Incorporated in Delhi in Sep’2019, KRM Ayurveda has moved from a product-sales model towards a combination of Ayurvedic products and healthcare services. It treats kidney disorders, liver cirrhosis, diabetes, fatty liver and arthritis, among other conditions. The company reports operating 6 hospitals and 5 clinics; 3 hospitals are NABH-accredited. Its Kundli, Haryana facility makes classical and proprietary Ayurvedic medicines and nutraceuticals.
Investment Rationale
- Growing services contribution: Services revenue rose from INR 6.5 Cr. in FY24 to INR 27.3 Cr. in FY25, increasing its share of revenue from 9.7% to 35.7%. Management has shifted resources towards hospital-based services.
- Higher hospital utilisation: Reported bed occupancy increased from 29.41% in FY24 to 84.87% in FY25, while hospital revenue rose from INR 5.3 Cr. to INR 25.8 Cr.
- Telemedicine and facilities: The company uses teleconsultation to direct patients to its hospitals and clinics. It also manufactures its own medicines at a captive facility in Haryana.
- Qualified workforce: The report lists 31 qualified Ayurvedic physicians and 59 certified Ayurvedic therapists.
- Industry outlook cited: The report cites RHP estimates that the Indian AYUSH market could expand from $43.3 Bn. to $200 Bn. by 2030.
Business Model and Operations
The company combines inpatient and outpatient care, Panchakarma therapies, specialized clinics, wellness packages, medicine sales, and diet and lifestyle counselling. Its product mix is shifting as it expands services: products accounted for 64.3% of FY25 revenue, compared with 90.3% in FY24. The report attributes the FY24 revenue decline to the strategic shift away from product sales and towards hospital services.
Government schemes are an important source of hospital services revenue. The report states that around 80%+ of hospital services revenue comes through ECHS and CGHS empanelment, with payment cycles of about 150 to 180 days. KRM Ayurveda’s geographic revenue table shows Delhi revenue declining from INR 51.3 Cr. in FY23 to INR 22.2 Cr. in FY25, while Haryana revenue rose from INR 3.1 Cr. to INR 21.0 Cr. over the same period.
KRM Ayurveda Key Financials
| Particulars (INR Cr.) | FY23 | FY24 | FY25 | Sep’25 |
|---|---|---|---|---|
| Revenue (excl. other inc.) | 89.3 | 67.2 | 76.6 | 48.4 |
| Growth Rate Y-o-Y % | (24.8%) | 14.0% | ||
| EBITDA (excl. other inc.) | 11.0 | 7.3 | 19.1 | 12.8 |
| PAT | 7.6 | 3.4 | 12.1 | 8.1 |
| Gross Margin % | 79.1% | 85.1% | 87.6% | 82.5% |
| EBITDA % (excl. other inc.) | 12.4% | 10.9% | 25.0% | 26.5% |
| PAT % | 8.5% | 5.0% | 15.7% | 16.7% |
| Debt (Short+Long) | 19.9 | 23.2 | 31.2 | 25.1 |
| Debt/Equity | 2.4x | 2.0x | 1.3x | 0.7x |
| ROE % | 165.1% | 33.9% | 67.9% | 21.8% |
| ROCE % | 40.3% | 20.8% | 43.3% | 21.8% |
| CFO / EBITDA % | 31.8% | (12.2%) | (0.1%) | 23.7% |
FY25 revenue and profitability recovered from FY24, while the company reported INR 48.4 Cr. revenue and INR 8.1 Cr. PAT for Sep’25.
Valuation
The valuation page gives an IPO market capitalisation of INR 287 Cr. and a current market capitalisation of INR 485 Cr. It lists FY26 PE at 30.3x and FY27 PE at 22.5x, alongside estimated FY26 revenue of INR 100 Cr. and PAT of INR 16.0 Cr., and FY27 revenue of INR 135 Cr. and PAT of INR 21.6 Cr. The note does not state a target price, upside or recommendation.
- INR 485 Cr.
- Current market capitalisation
- 30.3x
- FY26 PE
- 22.5x
- FY27 PE
Key Risks
- Related-party sales: Related-party transactions represented 30.8% of revenue in FY25; the report names Karma Life Care LLC and Karma Online Services LLC.
- Working-capital requirements: The business needs inventory to support hospital services, while ECHS and CGHS payment cycles of 150 to 180 days contribute to higher receivables.
- Cash conversion: CFO / EBITDA was (12.2%) in FY24 and (0.1%) in FY25; the report links the negative figures to increases in receivables and inventory during the shift to services.
- Promoter litigation: The report cites outstanding consumer complaints against promoter Dr. Puneet Dhawan concerning alleged medical negligence and patients who lost their lives after medicines or treatment prescribed by the promoter.
- Execution and operating costs: Attrition was 78.5% in FY24 and ~32% in FY25. Advertisement expense was 29.0% of revenue in FY24 and 20.0% in FY25; the report also flags the challenge of maintaining consistent quality across locations.
Management
Dr. Puneet Dhawan is Promoter & MD. The report says he holds a Bachelor of Ayurvedic Medicine & Surgery from the University of Delhi and established Karma Ayurveda in Delhi in 2013. Mrs. Tanya Dhawan is a Non-Exec Director, and Mr. Sanchit Hans is a Whole Time Director. Mrs. Vandana Gupta and Ms. Laxmi are listed as Independent Directors.
Shareholding
| Particular | Pre-Issue % | Post-Issue % |
|---|---|---|
| Promoter & Promoter Group | 92.16% | 67.28% |
| Public | 7.84% | 32.72% |
The report states that the shares listed on the NSE SME exchange on 29-Jan’26. It records an IPO price band of INR 135/- and a listing price of INR 172 (~27.5% premium).
Peer Comparison
The report names Jeena Sikho Lifecare and Vaidya Sane Ayurved Laboratories as listed peers. It notes Jeena Sikho had 58 operational hospitals and 2,290 operational beds, and had reported positive CFO / EBITDA over FY21 to FY25. The comparison also says KRM Ayurveda matches Jeena Sikho in average revenue per bed, while Jeena Sikho has a lower contribution from government panel revenue and a better working-capital cycle.
Our View
KRM Ayurveda’s increasing services contribution and higher reported hospital occupancy accompany a recovery in FY25 revenue and profitability. The note also highlights long government-scheme payment cycles, related-party sales and promoter litigation. It does not provide a recommendation or share target price.
Standard disclosures
- Research Analyst has served as an officer, director or employee of subject company(ies): No
- We or our associates have received compensation from the subject company(ies) in the past 12 months: No
- We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
- We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months: No
- We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report: No
- We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies): No
- Nature of financial interest in subject company, if any: Nil
- We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of R: No
- Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report: No.
- We or our Associates or Research Analyst are engaged in market making of subject company: No
- By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
- There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.
Regulatory disclosures
Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in or guptanishant.iimi@gmail.com | Contact Number: 8171433387 | Website: www.mcapital.in | Twitter: @Mcapital_In